---
title: 'Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and
  Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk
  for Psychosis'
date: '2024-03-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38451304/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240307170638&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: This article describes the rationale, aims, and methodology of the Accelerating
  Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international
  collaboration to date that will develop algorithms to predict trajectories and outcomes
  of individuals at clinical high risk (CHR) for psychosis and to advance the development
  and use of novel pharmacological interventions for CHR individuals. We present a
  description of the participating research networks and the data ...
disable_comments: true
---
This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data ...